- Home
- MCRI vs NRIX Comparison
MCRI vs NRIX Comparison
Compare MCRI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- NRIX
- Stock Information
- Founded
- MCRI 1972
- NRIX 2009
- Country
- MCRI United States
- NRIX United States
- Employees
- MCRI N/A
- NRIX N/A
- Industry
- MCRI Hotels/Resorts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- NRIX Health Care
- Exchange
- MCRI Nasdaq
- NRIX Nasdaq
- Market Cap
- MCRI 1.9B
- NRIX 750.4M
- IPO Year
- MCRI 1993
- NRIX 2020
- Fundamental
- Price
- MCRI $92.15
- NRIX $11.90
- Analyst Decision
- MCRI Hold
- NRIX Strong Buy
- Analyst Count
- MCRI 5
- NRIX 14
- Target Price
- MCRI $97.60
- NRIX $26.29
- AVG Volume (30 Days)
- MCRI 85.0K
- NRIX 1.8M
- Earning Date
- MCRI 10-21-2025
- NRIX 10-09-2025
- Dividend Yield
- MCRI 1.30%
- NRIX N/A
- EPS Growth
- MCRI N/A
- NRIX N/A
- EPS
- MCRI 4.41
- NRIX N/A
- Revenue
- MCRI $539,635,000.00
- NRIX $83,687,000.00
- Revenue This Year
- MCRI $6.99
- NRIX $58.48
- Revenue Next Year
- MCRI $3.72
- NRIX N/A
- P/E Ratio
- MCRI $20.90
- NRIX N/A
- Revenue Growth
- MCRI 4.61
- NRIX 48.32
- 52 Week Low
- MCRI $69.99
- NRIX $8.18
- 52 Week High
- MCRI $113.88
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- MCRI 34.35
- NRIX 65.43
- Support Level
- MCRI $91.06
- NRIX $10.28
- Resistance Level
- MCRI $93.83
- NRIX $11.70
- Average True Range (ATR)
- MCRI 2.55
- NRIX 0.81
- MACD
- MCRI -0.45
- NRIX 0.23
- Stochastic Oscillator
- MCRI 21.53
- NRIX 84.06
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.